文献速递湿疹皮炎与荨麻疹

涅莫利珠单抗治疗6-12岁中重度瘙痒性特应性皮炎患儿68周长期疗效与安全性

Long-term (68 weeks) administration of nemolizumab in paediatric patients aged 6-12 years with atopic dermatitis with moderate-to-severe pruritus: efficacy and safety data from a phase III study.
PubMed 文献 · Br J Dermatol · 2025-01-01

这项III期研究的长期扩展期纳入89例6-12岁日本特应性皮炎伴中重度瘙痒患儿,在16周随机双盲安慰剂对照期后继续52周开放治疗(涅莫利珠单抗30 mg每4周一次)。至第68周,瘙痒和湿疹面积与严重度持续改善,家属负担和睡眠质量改善,安全性特征与≥13岁患者相似,未见迟发型治疗中出现的不良事件。

要点

  • 涅莫利珠单抗30 mg每4周一次联合外用药物治疗68周,患儿瘙痒和AD体征持续改善。
  • 第68周时5级瘙痒评分较基线平均变化-1.8,EASI较基线平均百分比变化-77.1%。
  • 长期安全性特征与≥13岁患者相似,未见迟发型治疗中出现的不良事件。

核心结论

  • 涅莫利珠单抗长期用于6-12岁特应性皮炎伴中重度瘙痒患儿具有安全性,并可在68周内改善瘙痒、皮肤症状及患者和照护者生活质量。

研究设计与样本

  • III期研究包括16周随机、安慰剂对照、双盲、平行组期,随后为52周长期治疗期,所有患者均接受涅莫利珠单抗30 mg每4周一次。
  • 共评估89例6-12岁日本特应性皮炎伴中重度瘙痒患儿,研究注册于日本临床试验注册库(jRCT2080225289)。

主要发现

  • 第16周至第68周疗效指标呈改善趋势,停药后随访期疗效持续。
  • 第68周时,全程接受涅莫利珠单抗治疗的患者5级瘙痒评分较基线平均(SD)变化为-1.8(0.8)。
  • 第68周时,平均瘙痒数值评定量表评分较基线平均(SD)百分比变化为-65.9(25.0),湿疹面积和严重度指数评分较基线平均(SD)百分比变化为-77.1(23.1)。
  • 湿疹家庭影响问卷数据显示,至第16周家属家务负担和父母/照护者疲劳减轻、家庭成员睡眠质量改善,第68周进一步改善。
  • 总体安全性特征与≥13岁接受涅莫利珠单抗治疗的患者相似,长期治疗期间未见迟发型治疗中出现的不良事件。

临床怎么用

  • 对于6-12岁中重度瘙痒性特应性皮炎患儿,可考虑涅莫利珠单抗30 mg每4周一次联合外用药物进行长期治疗。
  • 治疗期间应关注瘙痒、AD体征及患者和照护者生活质量的持续改善。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A phase III clinical trial in Japanese children aged 6-12 years with atopic dermatitis (AD) and inadequately controlled moderate-to-severe pruritus found that 16 weeks of nemolizumab treatment [30 mg every 4 weeks (Q4W)] was clinically effective and tolerable, with early improvement in pruritus and associated skin signs and a positive impact on patient quality of life (QoL). OBJECTIVES: To report the findings from the long-term extension period of the study, and evaluate the efficacy and safety profiles of nemolizumab when administered concomitantly with topical agents over 68 weeks. METHODS: The study included a 16-week randomized placebo-controlled double-blind parallel-group period during which patients received nemolizumab 30 mg or placebo Q4W; those who completed this period could enter a 52-week long-term treatment period during which all patients received nemolizumab Q4W. Efficacy endpoints assessed treatment impact on pruritus, AD signs and QoL. Treatment-emergent adverse events (TEAEs) were tabulated to evaluate long-term safety. The study was registered with the Japan Registry of Clinical Trials (jRCT2080225289). RESULTS: Among the 89 paediatric patients evaluated, efficacy outcome measures showed a tendency toward improvement between weeks 16 and 68, and sustained efficacy during the subsequent follow-up period after treatment cessation. At week 68, among patients who received nemolizumab treatment throughout the study, the mean (SD) change from baseline in the 5-level itch score was -1.8 (0.8), the mean (SD) percentage change from baseline in the Average Pruritus Numerical Rating Scale score was -65.9 (25.0), and the mean (SD) percentage change from baseline in the Eczema Area and Severity Index score was -77.1 (23.1). Data from the Dermatitis Family Impact questionnaire indicated that the burden of housework on family members and parent/caregiver fatigue were reduced and the sleep quality of family members was improved by week 16, with further improvement at week 68. The overall safety profile was similar to that recorded in nemolizumab-treated patients aged ≥ 13 years, with no late-onset TEAEs seen over long-term treatment. CONCLUSIONS: These data confirm the safety of long-term nemolizumab for paediatric patients with AD, and demonstrate improvements in pruritus, skin symptoms, and patient and caregiver QoL over 68 weeks of treatment. Nemolizumab is a new treatment for atopic dermatitis (or ‘AD’ for short). The drug is injected under the skin every 4 weeks. It can be used alongside other medicines that are applied to the skin surface. We have already shown that 16 weeks of treatment with nemolizumab improved itch, signs of AD and quality of life in Japanese children with AD who could not control their disease with other medicines. AD can be a lifelong condition and treatments may need to be used for more than 16 weeks. We looked at whether nemolizumab continued to work well and was safe for 68 weeks of treatment. There were 89 children aged 6 to 12 years in the study. We used rating scales and questionnaires to measure the severity of itch, AD eczema and inflammation, and the quality of life of the children and their families. We found that itch and signs of AD reduced over time. The effects continued even after treatment stopped. The children had a better quality of life and their family members reported that they were less tired and had better sleep. Most side effects were mild. We did not see any new side effects after long-term treatment. Based on this study, we can say that long-term treatment with nemolizumab is effective and safe for children with AD and inadequately controlled itch.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Igarashi A, Katsunuma T, Nagano Y, et al. Long-term (68 weeks) administration of nemolizumab in paediatric patients aged 6-12 years with atopic dermatitis with moderate-to-severe pruritus: efficacy and safety data from a phase III study. Br J Dermatol. 2025. PMID: 39607831. doi:10.1093/bjd/ljae458

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。